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Manufacturers of the equipment mentioned in the Laboratory Procedures section. 
 
Procedure Equipment Manufacturer 
PBMC pellets resuspension RNAlater® Solution Life Technologies, Carlsbad, CA 
Automated purification of total RNA QIAcube by RNeasy Mini kit QIAGEN, Venlo, The 
Netherlands 
RNA integrity analysis Agilent 2100 Bioanalyzer Agilent Technologies, Santa 
Clara, CA 
RNA reverse transcription into cDNA SuperScript® VILO cDNA Synthesis 
Kit 
Invitrogen, Life Technologies, 
Carlsbad, CA 
PCR reactions RealTime ready Custom RT-qPCR 
assays 
Roche, Basel, Switzerland 
PCR reactions RealTime Ready™ DNA Probes 
Master Mix 
Roche, Basel, Switzerland 
CEA, CYFRA21-1, CA125 and CA19-9 
plasma concentrations measurement 
Architect immunoassay analyser 
platform 
Abbott Diagnostics, Lake forest, 
IL 
 
  
Predictive Algorithm Development  
The final predictive algorithms were defined on the training and validation sets, which 
included 120 and 61 samples, respectively, (Figure 1).  
Firstly, we defined an algorithm based on the 29-gene expression profiles. We refer 
to it as a multi-gene multi-classifier (MGMC) algorithm since our algorithm definition 
strategy envisaged the combination of multiple classifiers. This choice was based on 
the fact that there is not a single optimal classification method and that model 
combination can improve the robustness and stability of the test and its accuracy31, 
32
. The process could be broken into the following steps: 
1. Classifier generation on the training set. In order to define optimal classifiers for 
different classification problems, the following data subsets were used for model 
fitting: Controls + CRC stage I-IV, Controls + LAP, Controls + CRC stage I-II, 
Controls + Advanced Neoplasia (LAP+CRC I-IV). 144 statistical and 7200 fuzzy 
classifiers were generated and internally validated by non-overlapped bootstrap. 
1000 random datasets were drawn with replacement with the same size as the 
training set. The model was re-fitted on each bootstrap and validated on the out-
of-bag samples. The specificity and sensitivity average values over 1000 
bootstraps were calculated, Receiver Operating Characteristics (ROC) curves 
were generated and the area under the curve (AUC) was calculated. External 
validation on an independent validation set and performance estimation. 
2. Selection of the best performing classifiers. Twelve classifiers (6 statistical and 6 
fuzzy models) where selected according to the highest and most stable accuracy. 
Stable classifiers were defined as the ones showing the minimum distance for 
sensitivity and specificity across training, bootstrap and validation set. 
3. To define the MGMC algorithm we repeated steps 1-3, using the 12 classifiers as 
variables instead of the 29 biomarkers.  
Among several tested MGMCs, only one was retained and tested on the 
independent test sets. The final MGMC algorithm combines 5 classifiers fitted on 
different classification problems and releases a binary result which suggests the 
presence or absence of colorectal neoplasia. 
Once the MGMC algorithm was defined, we combined it with tumor protein 
markers, to give rise to a MGMC-Protein (MGMC-P) algorithm. First, the Wilcoxon 
rank test was applied to CEA, CYFRA21-1, CA125 and CA19-9 plasma 
concentrations, using the same data subsets described above, to select the most 
significant tumor markers for CRC discrimination from the control group. For 
selected markers, a cut-off value was defined by ROC curve analysis and by 
optimal trade-off selection between sensitivity and specificity. They were then 
combined with the MGMC algorithm, using a simple decision tree classification 
approach. The node rules were set in such a way that the sensitivity of the MGMC 
algorithm was maintained and the specificity was complemented and improved. The 
selection and validation of the MGMC-P algorithm followed steps 1-3 described 
above. 
Supplementary Table 1. The 29-gene panel for colorectal cancer and large adenoma 
detection. Gene expression profiles obtained from the training set were explored by 
univariate analysis to compare the behavior of the 29 genes across the control (CON), the 
CRC and the LAP groups. Twelve genes were significantly differentially expressed in CRC 
and LAP compared to controls (p-value<0.05) by Wilcoxon rank test, applied to normalized 
gene expressions. Relative abundance of a gene transcript is represented by the fold change 
(FC), defined as 𝐹𝐹𝐹𝐹𝑔𝑔𝑔𝑔𝑔𝑔𝑔𝑔 = 2∆∆𝐶𝐶𝐶𝐶 , where ∆∆𝐹𝐹𝐶𝐶 = 𝑚𝑚𝑚𝑚𝑚𝑚𝑚𝑚(∆𝐹𝐹𝐶𝐶𝐷𝐷𝐷𝐷𝐷𝐷𝑔𝑔𝐷𝐷𝐷𝐷𝑔𝑔)−𝑚𝑚𝑚𝑚𝑚𝑚𝑚𝑚(∆𝐹𝐹𝐶𝐶𝐶𝐶𝐶𝐶𝑔𝑔𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶).  
 
Gene Description Biological Function  p-value  CRC/CON  
FC 
CRC/CON 
 p-value  
LAP/CON 
FC  
LAP/CON  
S100 calcium binding protein A8  
Cytokine / Chemotaxis/inflammation 5.07E-06 1.7 1.79E-01 1.1 
interleukin 1, beta  
Cytokine / Chemotaxis/inflammation 4.19E-04 2.1 1.23E-03 1.7 
chemokine (C-C motif) receptor 1  Cell signal 
transduction/Chemotaxis/Inflammation 
4.42E-04 1.7 6.85E-03 1.3 
prostaglandin-endoperoxide synthase 2   
Lipid metabolism/Inflammation 7.68E-04 2.1 6.85E-03 1.6 
peroxisome proliferator-activated receptor 
gamma 
Transcription Regulation/ Proliferation/ 
Differentiation 
3.59E-03 1.4 1.36E-01 1.1 
mitogen-activated protein kinase 6  
Cell signaling/Proliferation 3.95E-03 1.2 6.01E-02 1.1 
tumor necrosis factor (ligand) superfamily, 
member 13b  Cytokine/ Chemotaxis/inflammation 
1.03E-02 1.2 7.82E-03 1.2 
calcium channel, voltage-dependent, beta 4 
subunit  Cell signal transduction/Ion transport 
1.31E-02 -1.3 4.24E-01 -1.1 
matrix metallopeptidase 11 (stromelysin 3)  
Protease/ Matrix remodelling 
1.66E-02 -1.3 7.60E-02 -1.2 
lactotransferrin  
Antimicrobial/Iron transport 2.14E-02 2.4 6.71E-02 1.6 
CD63 molecule  
Signal transduction 3.14E-02 1.1 2.18E-02 1.1 
carboxylesterase 1  
Esterase/ Drug metabolism 5.70E-02 1.2 5.05E-01 -1.0 
chemokine (C-X-C motif) ligand 10  
Cytokine / Chemotaxis/inflammation 7.13E-02 -1.3 4.43E-01 1.1 
mitogen-activated protein kinase kinase 3  
Cell signaling/Proliferation 9.89E-02 1.1 3.47E-02 1.1 
matrix metallopeptidase 9 (gelatinase B)  
Protease/ Matrix remodelling 1.21E-01 1.4 9.06E-01 -1.0 
B-cell CLL/lymphoma 3  
Transcription Regulation/ Cell Cycle 1.67E-01 1.1 7.82E-01 -1.1 
ras homolog gene family, member C  
Transcription Regulation/Motility 2.02E-01 -1.1 1.58E-01 1.1 
chemokine (C-X-C motif) ligand 11  
Cytokine / Chemotaxis/inflammation 3.20E-01 -1.2 4.08E-01 1.1 
prostaglandin E synthase  
Lipid metabolism/Inflammation 3.28E-01 -1.3 7.82E-01 1.0 
early growth response 1  
Transcription Regulation/Proliferation 3.79E-01 1.4 7.94E-02 1.7 
integrin, alpha 2 (CD49B)  
Cell signal transduction/Cell adhesion 3.90E-01 1.2 5.84E-01 1.2 
jun proto-oncogene  
Transcription Regulation/Proliferation 5.61E-01 -1.1 5.64E-01 -1.1 
GATA binding protein 2  Transcription 
Regulation/Proliferation/Differentiation 
6.40E-01 -1.1 7.36E-01 1.1 
non-metastatic cells 1, protein (NM23A)  
Transcription  Regulation/ Cell Cycle 7.39E-01 1.0 4.75E-01 1.0 
integrin, beta 5  
Cell signal transduction/Cell adhesion 7.85E-01 1.1 5.05E-01 1.1 
chemokine (C-X-C motif) receptor 3  Cell signal 
transduction/Chemotaxis/inflammation 
8.04E-01 -1.0 8.84E-01 -1.0 
FXYD domain containing ion transport 
regulator 5  Cell signal transduction/Ion transport 
9.48E-01 1.0 8.52E-01 -1.0 
male-specific lethal 1 homolog (Drosophila)  Transcription Regulation /Histone 
acetyltransferase 
9.60E-01 -1.0 2.07E-01 1.0 
interleukin 8  
Cytokine / Chemotaxis/inflammation 9.76E-01 1.0 7.27E-01 -1.0 
 
Table	  S2.	  Gene	  expression	  analysis	  of	  the	  29	  biomarkers	  according	  to	  age	  and	  sex	  in	  the	  3	  main	  study	  groups.	  
Two	  sided	  t-­‐test	  was	  used	  to	  test	  genes	  differentially	  expressed	  between	  subjects	  younger	  or	  older	  than	  65	  years	  or	  between	  males	  and	  females.	  
Statistical	  significance	  threshold	  was	  set	  at	  0.05.
CON LAP CRC CON LAP CRC
Genes p-­‐value p-­‐value p-­‐value p-­‐value p-­‐value p-­‐value
BCL3 5.7E-­‐01 8.2E-­‐01 3.6E-­‐01 9.8E-­‐01 3.8E-­‐01 8.1E-­‐01
CACNB4 9.0E-­‐01 2.1E-­‐01 6.3E-­‐01 4.8E-­‐01 2.1E-­‐02 1.4E-­‐02
CCR1 9.7E-­‐01 1.0E-­‐01 4.3E-­‐01 1.3E-­‐01 1.2E-­‐01 1.1E-­‐01
CD63 2.3E-­‐01 2.6E-­‐01 1.7E-­‐03 2.9E-­‐01 3.9E-­‐01 9.3E-­‐01
CES1 7.7E-­‐01 7.7E-­‐01 9.4E-­‐01 4.3E-­‐01 9.2E-­‐01 1.7E-­‐02
CXCL10 7.7E-­‐01 9.2E-­‐01 5.6E-­‐01 7.8E-­‐01 5.1E-­‐01 4.6E-­‐02
CXCL11 9.0E-­‐01 9.6E-­‐01 6.2E-­‐01 3.9E-­‐01 8.7E-­‐01 1.2E-­‐01
CXCR3 2.9E-­‐01 2.1E-­‐01 1.0E-­‐01 1.9E-­‐03 7.4E-­‐01 1.0E-­‐01
EGR1 4.6E-­‐01 9.7E-­‐01 7.6E-­‐01 4.1E-­‐01 1.1E-­‐01 7.8E-­‐01
FXYD5 7.4E-­‐01 6.8E-­‐01 2.3E-­‐01 1.8E-­‐01 6.3E-­‐01 7.5E-­‐01
GATA2 2.0E-­‐01 1.1E-­‐01 6.1E-­‐01 2.2E-­‐01 1.6E-­‐01 3.2E-­‐01
IL1B 8.8E-­‐01 1.3E-­‐01 7.7E-­‐01 2.2E-­‐01 5.9E-­‐02 1.4E-­‐01
IL8 8.3E-­‐01 8.9E-­‐01 1.6E-­‐01 4.5E-­‐01 6.4E-­‐01 4.9E-­‐01
ITGA2 6.2E-­‐01 7.2E-­‐01 1.0E-­‐01 3.8E-­‐01 1.6E-­‐04 2.3E-­‐01
ITGB5 9.2E-­‐01 8.8E-­‐01 1.7E-­‐02 8.8E-­‐01 7.5E-­‐04 3.7E-­‐01
JUN 2.5E-­‐01 7.4E-­‐01 5.0E-­‐01 1.8E-­‐01 2.9E-­‐01 5.3E-­‐01
LTF 5.1E-­‐01 5.4E-­‐01 3.1E-­‐01 9.2E-­‐01 5.5E-­‐01 3.2E-­‐01
MAP2K3 2.8E-­‐01 6.7E-­‐01 5.8E-­‐03 7.0E-­‐01 4.2E-­‐01 7.7E-­‐01
MAPK6 9.0E-­‐01 5.4E-­‐02 3.3E-­‐02 9.0E-­‐01 5.8E-­‐01 6.2E-­‐01
MMP11 3.8E-­‐01 1.7E-­‐01 2.3E-­‐02 1.1E-­‐02 7.0E-­‐01 6.6E-­‐01
MMP9 9.2E-­‐01 5.3E-­‐01 8.5E-­‐04 7.7E-­‐06 1.7E-­‐01 2.7E-­‐01
MSL1 7.8E-­‐01 3.5E-­‐01 4.1E-­‐01 4.8E-­‐01 7.9E-­‐01 4.8E-­‐02
NME1 7.9E-­‐01 8.7E-­‐01 9.9E-­‐01 7.7E-­‐01 2.9E-­‐01 7.1E-­‐01
PPARG 8.4E-­‐01 5.9E-­‐01 3.3E-­‐01 2.9E-­‐01 7.9E-­‐04 3.9E-­‐01
PTGES 7.8E-­‐01 7.3E-­‐01 7.5E-­‐01 1.4E-­‐02 4.5E-­‐01 9.8E-­‐01
PTGS2 9.1E-­‐01 1.1E-­‐01 4.3E-­‐01 9.7E-­‐01 1.4E-­‐01 2.7E-­‐01
RHOC 5.5E-­‐01 2.6E-­‐01 1.8E-­‐02 9.9E-­‐02 5.8E-­‐01 7.7E-­‐01
S100A8 6.2E-­‐01 1.1E-­‐01 1.1E-­‐02 2.3E-­‐02 2.0E-­‐01 8.2E-­‐01
TNFSF13B 6.1E-­‐01 9.1E-­‐01 1.7E-­‐01 4.2E-­‐01 7.6E-­‐01 3.2E-­‐01
Age	  (<65y	  vs	  >65y) Sex	  (M	  vs	  F)
Table S3. Positive rate of the MGMC and MGMC-P algorithms for 
non-colorectal cancers  
 
 
 
 
 
 
 
 
 
MGMC MGMC-P 
 
Total 
Positive 
rate 
Positive 
rate 
 n % % 
Other cancers, total a  : 63 63.5 66.7 
GI cancers other than CRC b 15 80.0 66.7 
Pancreatic cancer 12 41.7 66.7 
Prostate cancer 20 60.0 55.0 
Lung and tracheal cancers 11 72.7 81.8 
Breast, ovary and endometrial cancers 4 50.0 75.0 
a One metastatic cancer of unknown origin 
b Five Esophageal, 4 Gastric, 3 Liver, 2 Bile 
duct and 1 Duodenal cancer 
 
 
   
Supplementary Table S4.  
Positive rate of the predictive MGMC and MGMC-P 
algorithms applied to non per-protocol cases.  
 
  MGMC MGMC-P 
 
Total Positive Positive 
n (% % 
Controlsa 16 6.2 6.2 
LAPb 23 56.5 52.1 
CRC c 21 90.5 85.7 
CRC stage unknown 8 50.0 50.0 
AP<1cmb 48 35.4 31.2 
Other medical conditions 
and diseasesd 
42 54.7 40.5 
Other cancerse 30 70.0 66.6 
a These subjects presented with  a personal history of polyps or asthma with 
ongoing treatment 
b Most of the cases presented with concomitant hyperplastic polyps, 
inflammatory diseases or gallstones 
C The majority of the cases presented with concomitant gallstones, bacterial 
infections under treatment or other types of cancer. 
d Cases were presenting with abnormal laboratory parameters, transplantation, 
co-morbidities including inflammatory and/or autoimmune disease, etc. 
e Most of the cases presented concomitant adenomas, bacterial infections 
under treatment or gallstones 
Variable Class Total	  Control
MGMC
Positive	  (%)
MGMC-­‐P
Positive	  (%)
p-­‐value*
MGMC
p-­‐value*
MGMC-­‐P Total	  CRC
MGMC
Positive	  (%)
MGMC-­‐P
Positive	  (%)
p-­‐value*
MGMC
p-­‐value*
MGMC-­‐P
50-­‐64 59 6	  (10.2) 3	  (5.1) 16 12	  (75.0) 11	  (68.8)
>65 31 3	  (9.7) 4	  (12.9) 57 46	  (80.7) 46	  (80.7)
female 42 5	  (11.9) 4	  (9.5) 32 27	  (84.4) 25	  (78.1)
male 48 4	  (8.3) 3	  (6.3) 41 31	  (75.6) 32	  (78.1)
19 13	  (68.4) 14	  (73.7)
33 26	  (66.7) 26	  (66.7)
*	  two	  sided	  Fisher's	  exact	  test,	  p>0.05	  is	  considered	  statistically	  significant
Sex
0.32
0.73 0.70 0.40 1.00
1.00 0.23 0.73
Table	  S5.	  Positivity	  of	  Colox	  test	  by	  age,	  sex	  and	  type	  of	  recrutment
Age
Controls CRC
0.51 0.739Type	  of	  recrutment
Colonoscopy	  
Surgery
